Head & Neck · Organ at risk

Larynx

Educational Summary

Dose constraints

Head & Neck Planning Essentials

ScheduleConstraintSource
Conventional fractionation
70 Gy / 35 fx definitive · 60–66 Gy / 30–33 fx post-op
Mean ≤45 GyRTOG 0615

Glottic and supraglottic larynx, when it is not part of the target.

Quoted from eviQ 5049, checked 2026-09-24. Full table with references →

Anatomy

The voice box, below the hyoid bone and above the trachea, containing the supraglottis (epiglottis and false cords), the glottis (true vocal cords) and the subglottis.

Function in the body

The voice box. The vocal cords make the voice, and the larynx closes over the airway during swallowing so food and liquid do not go into the lungs.

Why it matters

Dose to the larynx can cause edema, hoarseness and swallowing problems. It is spared when the target is elsewhere — oral cavity, oropharynx, nasopharynx — and is part of the target in larynx cancer, where the limit does not apply.

How to contour

Brouwer 2015 splits the larynx into two structures (Table 1), following Christianen 2011 for the supraglottic part.

Supraglottic larynx

  • Top: the tip of the epiglottis. Bottom: the top edge of the arytenoid cartilages.
  • Front: the hyoid bone, the pre-epiglottic space and the thyroid cartilage.
  • Back: the inferior pharyngeal constrictor and the pharyngeal lumen.
  • Sides: the thyroid cartilage. Inside: the pharyngeal lumen — the air is left out.

Glottic area (the vocal cords and the fat around them, with the air left out)

  • Top: the top edge of the arytenoid cartilages.
  • Bottom: the lower edge of the front of the thyroid cartilage.
  • Back: the cricoid and the front edge of the arytenoids.

RTOG 0920 instead defines a single glottic/supraglottic larynx (GSL) structure from just below the hyoid to the cricoid cartilage — check which your protocol uses.

Further reading

  • RTOG 0615 — RTOG 0615 protocol — A Phase II Study of Concurrent Chemoradiotherapy Using Three-Dimensional Conformal Radiotherapy (3D-CRT) or Intensity-Modulated Radiation Therapy (IMRT) + Bevacizumab (BV) for Locally or Regionally Advanced Nasopharyngeal Cancer Source

Related concepts